Stock NTRA NATERA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Natera, Inc.

Equities

NTRA

US6323071042

Real-time Estimate Cboe BZX
Other stock markets
 09:46:22 2024-05-20 am EDT 		5-day change 1st Jan Change
107.2 USD +0.73% Intraday chart for Natera, Inc. +3.15% +70.16%
May. 14 Piper Sandler Adjusts Price Target on Natera to $120 From $110, Maintains Overweight Rating MT
May. 13 BTIG Raises Price Target on Natera to $125 From $100, Maintains Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Piper Sandler Adjusts Price Target on Natera to $120 From $110, Maintains Overweight Rating
MT
BTIG Raises Price Target on Natera to $125 From $100, Maintains Buy Rating
MT
Natera Insider Sold Shares Worth $3,137,567, According to a Recent SEC Filing
MT
Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024
AQ
Baird Adjusts Natera Price Target to $117 From $99, Maintains Outperform Rating
MT
UBS Boosts Price Target on Natera to $160 From $104, Keeps Buy Rating
MT
Top Premarket Gainers
MT
Natera Q1 Loss Narrows, Revenue Rises; Full-Year Revenue Guidance Raised -- Shares Jump After Hours
MT
Natera: Q1 Earnings Snapshot
AQ
Natera : Q1 2024 Earnings Presentation
PU
Natera, Inc. Provides Earnings Guidance for the Year 2024
CI
Transcript : Natera, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (NTRA) NATERA Reports Q1 Revenue $367.7M, vs. Street Est of $315.3M
MT
Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Natera Reports First Quarter 2024 Financial Results
BU
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera in Breast Cancer
AQ
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
BU
Natera, Inc. Announces a New Publication in JCO Precision Oncology Reporting on the Ability of its Personalised and Tumor-Informed Molecular Residual Disease Test, Signatera
CI
Natera to Report its First Quarter 2024 Results on May 9
BU
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NTRA Stock
  4. News Natera, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW